- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 386
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Cutaneous T-cell Lymphoma
- Interventions
- anti-thymocyte globulin, cyclosporine, Lymphoid radiation
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Systemic Sclerosis
- Interventions
- anti-thymocyte globulin, cyclophosphamide
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Durham, North Carolina • Seattle, Washington
- Conditions
- Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
- Interventions
- Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, filgrastim, methotrexate, allogeneic hematopoietic stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Fairview University Medical Center
- Other
- Eligibility
- 0 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Preparative Regimen, NK Cells, Interleukin-2, CD34 Graft/Anti-thymocyte globulin, Donor TCR α/β-depleted Graft/ATG
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Minneapolis, Minnesota • St Louis, Missouri + 1 more
- Conditions
- Leukemia
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cytarabine, methylprednisolone, thiotepa, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Severe Aplastic Anemia
- Interventions
- Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide, Total Body Irradiation (TBI), Haplo HSCT, Tacrolimus, Mycophenolate mofetil (MMF), G-CSF
- Drug · Radiation · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 28
- States / cities
- Duarte, California • Los Angeles, California • Oakland, California + 24 more
- Conditions
- Diabetes Mellitus, Type I
- Interventions
- Purified Pancreatic Islets, Etanercept
- Biological · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End-Stage Renal Disease, Kidney Failure
- Interventions
- Single-dose rabbit Anti-thymocyte Globulin induction, Divided-dose rabbit Anti-thymocyte Globulin induction
- Biological
- Lead sponsor
- Wright State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Omaha, Nebraska • Winston-Salem, North Carolina + 1 more
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
- Interventions
- Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Chimeric Therapies
- Industry
- Eligibility
- 12 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 15
- States / cities
- La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
- Conditions
- Acute (Cellular) Renal Allograft Rejection
- Interventions
- rATG
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Mannosidosis, Mucolipidosis Type II (I-cell Disease)
- Interventions
- Stem Cell Transplant, Busulfan, Cyclophosphamide, ATG
- Procedure · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Aplastic Anemia
- Interventions
- cyclosporine, anti-thymocyte globulin
- Drug · Biological
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Renal Transplant
- Interventions
- Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • Atlanta, Georgia
- Conditions
- Graft vs Host Disease
- Interventions
- Low Dose Thymoglobulin (ATG), High Dose Thymoglobulin (ATG)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
- Interventions
- Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
- Drug · Radiation
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 8 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Aplastic Anemia, Bone Marrow Failure Syndrome
- Interventions
- Anti-Thymocyte Globulin (Rabbit), Fludarabine, Cyclophosphamide, Mesna, G-CSF, Total Lymphoid Irradiation (TLI), CliniMACS, HPC, A Infusion, CD45RA-depleted DLI
- Drug · Radiation · Device + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Ischemia Reperfusion Injury, Heart Transplantation
- Interventions
- Anti-Thymocyte Globulin, Normal Saline
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
- Interventions
- anti-thymocyte globulin, therapeutic allogeneic lymphocytes, fludarabine phosphate, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- San Francisco, California • Chapel Hill, North Carolina